IVX Shares Invion Limited
ASX · ASXLast in our picks 2026-10-05 — not in the current list; analysis below is from that screen
Highly speculative biotech with optionality, best suited only for risk-tolerant investors.
Signal breakdown
- ▸No clear institutional accumulation signal.
- ▸Above 50-day MA (+6.33%)
- ▸Volume 2.71× average — accumulation
- ▾Near 52-week low (12.8% of range)
Is IVX a buy right now?
Trend: IVX is trading below the 50-day average (-7.50%), RSI 40 — neutral momentum, with a 3-month return of -9.76%.
Valuation & quality: Invion Limited trades on price-to-book 0.76; fundamentals show net margin 0.0%, return on equity -83.0%, revenue growth 12675.9% year on year.
Our screen: BUY (score 2) — Highly speculative biotech with optionality, best suited only for risk-tolerant investors.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -12.50% | -14.30% | -33.30% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Invion Limited
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.